Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

SELECT-2: a Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy of Selumetinib Plus Docetaxel As a Second-Line Treatment of Patients with Advanced or Metastatic Non-Small-cell Lung Cancer.

J. -C. Soria, A. Fueloep,C. Maciel,J. R. Fischer,G. Girotto, S. Lago,E. Smit,G. Ostoros,W. E. E. Eberhardt, P. Lishkovska,S. Lovick,G. Mariani, A. McKeown,E. Kilgour,P. Smith,K. Bowen,A. Kohlmann,D. J. Carlile,P. A. Jaenne

Annals of Oncology（2017）

Cited 26|Views0
Key words
advanced non-small-cell lung cancer (NSCLC),metastatic disease,MEK1/2,KRAS,selumetinib,docetaxel
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined